ANAVEX 3-71
Alternative Names: AF-710B; ANAVEX-3-71Latest Information Update: 28 Mar 2024
Price :
$50 *
At a glance
- Originator Life Science Research Israel
- Developer Anavex Life Sciences; Life Science Research Israel
- Class Anti-inflammatories; Antidementias; Antiparkinsonians; Neuroprotectants; Nootropics; Small molecules
- Mechanism of Action Apoptosis stimulants; Muscarinic M1 receptor agonists; Sigma-1 receptor agonists; Sigma-2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Schizophrenia
- No development reported Alzheimer's disease; Frontotemporal dementia; Parkinson's disease; Unspecified
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for phase-I development in Frontotemporal dementia in USA (PO)
- 28 Mar 2024 No recent reports of development identified for phase-I development in Unspecified(In volunteers) in Australia (PO)
- 28 Mar 2024 No recent reports of development identified for preclinical development in Alzheimer's-disease in Israel (PO)